pemetrexed + gemcitabine

Phase 2Completed

2 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Breast Cancer

Conditions

Breast Cancer

Trial Timeline

Oct 1, 2004 → Nov 1, 2005

NCT ID

NCT00191347

About pemetrexed + gemcitabine

pemetrexed + gemcitabine is a phase 2 stage product being developed by Eli Lilly for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00191347. Target conditions include Breast Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Breast Cancer were approved

Approved (20) Terminated (4) Active (0)

✅arzoxifeneEli LillyApproved

✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved

✅Eribulin mesylateEisaiApproved

✅Eribulin MesylateEisaiApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved

✅Abemaciclib + Fulvestrant + Standard ChemotherapyEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00034489	Phase 2	Completed	—	—	Breast Neoplasms
NCT00383331	Phase 2	Terminated	Feb 1, 2007	Jan 1, 2008	Non-Small-Cell Lung Cancer
NCT00394147	Phase 2	Terminated	Oct 1, 2006	Dec 1, 2009	Head and Neck Cancer
NCT00491075	Phase 2	Terminated	Dec 1, 2005	Sep 1, 2011	Renal Cell Carcinoma
NCT00193414	Phase 2	Completed	May 1, 2005	Aug 1, 2009	Lung Cancer
NCT00191503	Phase 2	Completed	Jan 1, 2005	Nov 1, 2005	Adenocarcinoma
NCT00191347	Phase 2	Completed	Oct 1, 2004	Nov 1, 2005	Breast Cancer
NCT00071136	Phase 1/2	Completed	Dec 1, 2003	Aug 1, 2006	Lung Neoplasms
NCT00489983	Phase 2	Completed	Jul 1, 2003	Mar 1, 2005	Non-Small Cell Lung Cancer
NCT00061464	Phase 2	Completed	Feb 1, 2003	Feb 1, 2006	Carcinoma, Non-Small-Cell Lung
NCT00061451	Phase 2	Completed	Dec 1, 2002	Sep 1, 2006	Carcinoma, Non-Small-Cell Lung
NCT00061477	Phase 2	Completed	Dec 1, 2002	Sep 1, 2006	Mesothelioma

Competing Products

20 competing products in Breast Cancer

See all competitors

Product	Company	Stage	Hype Score
Intratumoral Mitazalimab + Intratumoral Nivolumab	Alligator Bioscience AB	Phase 1	26
Fulvestrant	Dr. Reddy's Laboratories	Pre-clinical	19
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	30
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	35
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	35
Abemaciclib + Fulvestrant	Eli Lilly	Phase 2	27
VS-6766 + Abemaciclib + Fulvestrant	Eli Lilly	Phase 1/2	39
gemcitabine + vinorelbine	Eli Lilly	Phase 2	35
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	44
Azenosertib + Carboplatin + Pembrolizumab	Zentalis Pharmaceuticals	Phase 1/2	26
Abemaciclib	Eli Lilly	Pre-clinical	26
pemetrexed + cyclophosphamide + doxorubicin + docetaxel	Eli Lilly	Phase 2	35
arzoxifene	Eli Lilly	Approved	43
BBI-355 + Erlotinib + Futibatinib + BBI-825	Boundless Bio	Phase 1	23
BBI-940 + Fulvestrant	Boundless Bio	Phase 1	26
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant	Eli Lilly	Phase 3	47
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: Sorafenib	Eli Lilly	Phase 2	27